

# Imaging of Ra-223 with a small-pixel CdTe detector: potential for improved image quantification for radionuclide dosimetry

**James Scuffham**<sup>1,2</sup>

Silvia Pani<sup>2</sup>, Paul Seller<sup>3</sup>, Paul J Sellin<sup>2</sup>, Matthew C Veale<sup>3</sup>, Matthew D Wilson<sup>3</sup>, Robert J Cernik<sup>4</sup>

1. Department of Nuclear Medicine, Royal Surrey County Hospital, Guildford, UK.
2. Department of Physics, University of Surrey, Guildford, UK
3. STFC Rutherford Appleton Laboratory, Didcot, UK
4. School of Materials, University of Manchester, UK

# Prostate Cancer


- Most prevalent cancer in men (>40,000 diagnoses per year; 13% of all cancers; 25% of new cases in men)<sup>i</sup>
- Highest incidence in the 75-79 age group<sup>i</sup>
- 81.4% survive more than 5 years<sup>i</sup>
- Commonly spreads to the bones in advanced disease (~90% of patients with castration-resistant, prostate cancer (CRPC) have bone metastases)<sup>ii</sup>



i – ONS Cancer Statistics Registrations, June 2013

ii - Scher H, et al. N Engl J Med. 2012;367:1187-1197, supplemental appendix.


# Bone metastases



- Metastases are common in the ribs, spine, pelvis and hips
- Can cause debilitating pain and severely impact quality of life
- Treatments are palliative


# Xofigo®

- New radiopharmaceutical ( $^{223}\text{RaCl}_2$ ) by Bayer
- Bone-seeking alpha-emitter
- Licensed in the UK in Feb 2014 after promising clinical trial results:




- **Increased median overall survival of 3.6 months**
- Increased time to serious skeletal event (5.8 months)
- Increased time to Alkaline Phosphatase progression (3.6 months)

# The Alpha Advantage



Range of  $\alpha$ -particle:  
(short range - 2 to 10 cell  
diameters). High LET, increased  
chance of double-strand DNA  
breaks




Range of  $\beta$ -particle:  
(long range - 10 to 1000 cell  
diameters)

# The Disadvantages

- $^{223}\text{Ra}$ 's emissions are not optimal for imaging with conventional gamma cameras



- Injected activities are generally around 6MBq  $\rightarrow$  very low external dose rate (good for patients' family, not good for imaging!).





# Why do we need imaging?


- Currently very simplistic administration regimen based on patient weight (50kBq/kg)
- BUT...patient weight does not necessarily correlate to tumour burden, radiopharmaceutical uptake, or even the patient's bone marrow reserve
- Therapy could be tailored to the individual patient by adjusting administered activity based on uptake and clearance in the bone
- Need to image the biodistribution and clearance of radiopharmaceutical, as this varies greatly between patients
- → **“Personalised medicine”**

# Imaging with gamma cameras

Typical Energy Spectra:



Typical Patient Images (MEGP):



Hindorf et al, NMC 2012




# The HEXITEC Detector




- 1mm thick CdTe
- 80 x 80 pixels, 250 $\mu$ m pitch
- 5-200keV spectroscopy per pixel
- 10000 frames per second
- -500V detector bias
- Peltier cooling, room temperature operation

- Corrections for charge sharing
- Pixelwise energy and uniformity calibrations
- Energy resolution 0.8% at 140keV (vs 9% for conventional gamma camera)




# HEXITEC Ra-223 Spectrum

- Glass vial containing ~6MBq Ra-223
- 3mm lead pinhole collimator
- Spectrum collected over 15 hours




# HEXITEC Imaging with Ra-223

- “Body phantom” containing 6 spheres (10, 13, 17, 22, 28, 37mm)
- Spheres: 434kBq/ml  
Cylinder: 2.4kBq/ml  
Cold background
- 3mm lead pinhole collimator at 28cm from spheres
- Planar acquisition, “tiled” with 4 stops
- 50mins “live time” per stop
- Bias refresh (60s on, 4s off, 6s settle)
- Energy calibration applied, form images with  $85 \pm 5$ keV energy window
- Stitch 4 tiles together




# Imaging Results

- 4 (5?) spheres visible
- Low counts; noisy image
- Detector edge effects due to “stitching”.
- Efficiency limited by pinhole collimation and distance from phantom



# Comparison with gamma camera



- GE Infinia SPECT/CT
- “Medium Energy” parallel-hole collimators
- 50mins,  $89.5 \pm 13.4\%$  keV
- 5 (6?) spheres visible?
- Better statistics
- Central compartment visible

# HEXITEC Ra-223 conclusions

- Spectroscopy is excellent  
→ potential for improved quantitative imaging due to improved scatter rejection
- Sensitivity with lead pinhole collimators too poor for clinical imaging
- Need higher sensitivity collimators
- Larger area detector would also be needed for clinical imaging

# Ongoing work – RAL and Surrey

- Simulation work to optimise parallel-hole collimator design for increased sensitivity for both Tc-99m and Ra-223
- Planning to test thicker CZT detector material shortly
- Large-area detectors under development (Seller et al, this morning at PSD)

